

Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Brendan M. Everett, MD, MPH, Marc Y. Donath, MD, Aruna D. Pradhan, MD, MPH, Tom Thuren, MD, Prem Pais, MD, Jose C. Nicolau, MD, Robert J. Glynn, ScD, Peter Libby, MD, Paul M. Ridker, MD, MPH

PII: S0735-1097(18)33483-1

DOI: [10.1016/j.jacc.2018.03.002](https://doi.org/10.1016/j.jacc.2018.03.002)

Reference: JAC 24732

To appear in: *Journal of the American College of Cardiology*

Received Date: 14 February 2018

Revised Date: 28 February 2018

Accepted Date: 1 March 2018

Please cite this article as: Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM, Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes, *Journal of the American College of Cardiology* (2018), doi: 10.1016/j.jacc.2018.03.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Brendan M. Everett, MD, MPH,^{a,b} Marc Y. Donath, MD,^c Aruna D. Pradhan, MD, MPH,^{a,d} Tom Thuren, MD,^e Prem Pais, MD,^f Jose C. Nicolau,^g MD, Robert J. Glynn, ScD,^a Peter Libby, MD,^b Paul M Ridker, MD, MPH^{a,b}

From the ^aCardiovascular Disease Prevention and the ^bDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; ^cEndocrinology, Diabetes & Metabolism, University Hospital Basel, Basel, Switzerland; ^dDivision of Cardiovascular Medicine, Department of Medicine, VA Boston Medical Center, West Roxbury, Massachusetts; ^eNovartis, East Hanover, NJ, and Basel, Switzerland; ^fSt. John's Research Institute, Bangalore, India; ^gInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Brief Title: Canakinumab for Diabetes Prevention and Management

Funding: Funded by Novartis, Basel, Switzerland

Disclosures: PMR, RJG, PP, and JCN received research grant support from Novartis Pharmaceuticals to conduct the CANTOS trial. PMR, BME, and PL have served as consultants to Novartis and BME has grant support from Novartis for work unrelated to CANTOS. PMR is listed as a co-inventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. TT is an employee of, and holds stock in, Novartis Pharmaceuticals. All other authors declare no competing interests.

Address for Correspondence:

Brendan M. Everett, MD, MPH
Brigham and Women's Hospital
Divisions of Preventive and Cardiovascular Medicine
900 Commonwealth Ave
Boston, MA 02215
Telephone: 857-307-1990
Fax: 857-307-1955
E-mail: beverett@bwh.harvard.edu
Twitter: [@brendan](https://twitter.com/brendan)

Download English Version:

<https://daneshyari.com/en/article/8666052>

Download Persian Version:

<https://daneshyari.com/article/8666052>

[Daneshyari.com](https://daneshyari.com)